Bio Green Med Solution, Inc.

AI-generated fair value estimate for this company.

Method: EV/Revenue comparable-multiple approach: $0.747M FY2025 revenue (fire-safety-equipment distribution business acquired via reverse merger with the former Cyclacel Pharmaceuticals shell) valued at a 1.5x EV/Revenue multiple typical of small, low-margin distribution businesses; no material net debt adjustment given limited reliable balance-sheet disclosure; 6.6M shares outstanding.

Reasoning: Bio Green Med Solution has only one year of financial history under its current fire-safety-distribution business (following a 2025 reverse merger) and negative operating margins, making a multi-year DCF unreliable; a conservative revenue-multiple approach anchored to comparable small distribution businesses is more defensible, and it implies the current market price is largely attributable to shell-company speculation rather than underlying distribution economics.